Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.34), $0.04 worse than the analyst estimate of ($0.30). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE